Vera Therapeutics initiated with a Buy at Goldman Sachs

Goldman Sachs analyst Paul Choi initiated coverage of Vera Therapeutics (VERA) with a Buy rating and $58 price target Following the recent pullback, the firm sees Vera shares as at “an attractive entry point” given atacicept is largely de-risked with line of sight to commercialization starting next year, the analyst tells investors. The firm’s checks indicate “significant enthusiasm” following the long term Phase 2b ORIGIN update, which suggests that atacicept can essentially restore normal kidney function in IgAN patients, the analyst noted.